Similarly, the combined treatment was more effective in reducing tumor cell viability in primary leukemic samples obtained from patients with B-cell chronic lymphocytic leukemia (B-CLL) and B cell lymphoma harboring wt p53 than each single drug (Figure 6A). Here, TP53 is linked to B-cell chronic lymphocytic leukemia.